KR102152182B1 - A composition for the prevention or treatment of depression, stress or memory malfunctions containing Geum aleppicum extract - Google Patents

Abstract

The present invention relates to a composition for improving, preventing or treating depressive symptoms or stress, and by containing a Geum aleppicum extract as an active ingredient, depressive symptoms or stress can be improved, prevented or treated. In addition, since it is not toxic, it can be consumed in the form of food.

Description

A composition for the prevention or treatment of depression, stress or memory malfunctions containing Geum aleppicum extract}

The present invention relates to a composition capable of improving, preventing or treating depressive symptoms or stress by containing an extract of Geum aleppicum as an active ingredient.

As society rapidly develops and diversifies, modern people are being asked for various roles. Accordingly, people complaining of mental disorders such as depression, anxiety disorder or sleep disorder due to various stresses are increasing. According to the 2006 epidemiological survey of mental illnesses conducted by the Ministry of Health and Welfare for adults aged 18 to 64 years old, the'one year prevalence of mental illness' was found to be 17.1%.

In addition, the'lifetime prevalence rate of mental illness', which is the percentage of the population who has experienced more than one mental illness over a lifetime, was also found to be 30%, which is one in three adults (as of 2006). In addition, adolescent mental disorders have recently increased due to excessive academic fever.

Stress refers to a state of physical or psychological pressure, which is caused by an element that is prevalent in everyday life and contributes to the occurrence of almost all psychiatric and medical diseases. However, if you fail to cope with stress and leave it unattended, psychological reactions such as depression, anxiety, fatigue, anger, and mood change occur, and physiological reactions such as α-wave reduction among EEG and increase in blood pressure and pulse rate are caused. If the reaction is repeated over and over again, illnesses such as depression, anxiety, and sleep disturbances develop, cause personal, family and social losses, and cause an individual's quality of life to deteriorate.

Among the diseases caused by stress, depression refers to a psychological state of stagnant mood characterized by feelings of sadness, hopelessness and frustration. In other words, it means a state that has developed into a major depressive disorder through normal emotions such as "depressiveness" and dysthymic disorder.

The main symptoms of depression include changes in taste, weight or sleep pattern, psychomotor agitation or retardation, decreased thinking ability, concentration or decision ability, lack of vitality and fatigue, feelings of worthlessness, feelings of self-confidence. Or a major depressive episode, which is a period in which a feeling of guilt, frequent death or suicidal thoughts, some of the plans or attempts to commit suicide, a period of depression in the day-to-day mood or loss of interest or enjoyment in most activities. It is characterized.

Currently, treatments for depressive symptoms used in clinical practice are generally developed and tested through animal models of depressive symptoms. All treatments for depressive symptoms are understood to have a drug action that enhances drug action at synapses by inhibiting the decomposition and reabsorption of monoamines such as dopamine, serotonin, and noepinephrine, which are neurotransmitters between brain neurons. However, since the drug has a large difference in efficacy depending on the patient, it is necessary to develop a new antidepressant that supplements or replaces this problem.

According to the statistics on the treatment of depressive symptoms recently released by the National Health Insurance Service, the number of depressed patients increased by 12.4% in 2011 compared to 2007. In 2009-2010, suicide caused by mental and psychiatric problems is the cause of suicide. It ranks first, and the number of people who committed suicide as a cause of this is increasing to 4,132 (28.1%) in 2009 and 4,357 (29.5%) in 2010. In addition to depression, attention deficit/hyperactivity disorder (ADHD) patients also increased from 48,000 in 2007 to 57,000 in 2012, an increase of 9,000 for five years, and an average annual increase of 4.4%. .

Therefore, depressive symptoms, stress or cognitive dysfunction can be quickly improved, prevented or treated, and there is a demand for extracts from natural products that are safe and have no side effects.

Republic of Korea Patent Publication No. 10-2014-0083867 Republic of Korea Patent Publication No. 10-2015-0077393

It is an object of the present invention to provide a pharmaceutical composition capable of preventing or treating depressive symptoms, stress, or cognitive dysfunction by containing the extract of a large snake radish as an active ingredient.

In addition, another object of the present invention is to provide a food composition capable of improving or preventing depressive symptoms, stress, or cognitive dysfunction by containing the extract of the big snake as an active ingredient.

The pharmaceutical composition for preventing or treating depressive symptoms, stress or cognitive dysfunction of the present invention for achieving the above object may contain a Geum aleppicum extract as an active ingredient.

The big snake radish extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof.

The lower alcohol having 1 to 4 carbon atoms may be 20 to 80% methanol, ethanol, butanol, or propanol.

The big snake mud extract may be an aqueous solution of 20 to 80% ethanol.

The extraction temperature may be 50 to 80 ℃.

When ingesting the pharmaceutical composition, sucrose intake may be as high as 65 to 85%.

After ingestion of the pharmaceutical composition, the immobility time during forced swimming may be as short as 80 to 120 seconds.

In addition, the food composition for improving or preventing depressive symptoms, stress, or cognitive dysfunction of the present invention for achieving the other objects described above may contain a Geum aleppicum extract as an active ingredient.

In addition, the functional feed additive composition of the present invention for achieving the another object described above may contain a Geum aleppicum extract as an active ingredient.

The composition for improving, preventing or treating depressive symptoms or stress containing the extract of Geum aleppicum of the present invention is not toxic, and has a very good effect of improving, preventing or treating depressive symptoms or stress. It is effective in the manufacture of food compositions and pharmaceutical compositions.

In addition, since the extract of Geum aleppicum of the present invention is not toxic, it can be used as a feed additive composition.

The present invention relates to a composition capable of improving, preventing or treating depressive symptoms, stress or cognitive dysfunction by containing extract of Geum aleppicum as an active ingredient.

Hereinafter, the present invention will be described in detail.

The composition for improving, preventing or treating depressive symptoms, stress or cognitive dysfunction of the present invention contains a Geum aleppicum extract as an active ingredient.

The big snake (Geum aleppicum) is called Asian herb bennet, and the dry above-ground part is used as a medicinal herb called Suyangmae (水楊梅). The big snake grows in grassland or waterside, and the stem is 30-100cm in height and has hairs spreading sideways. The leaves from the root have long petioles and are pinnate compound leaves composed of 2-5 pairs of small leaves.

In addition, the large Bammu uses the whole plant as a medicinal material in oriental medicine, and is effective for pain in the lower back and legs, dysentery, uterine bleeding, white corpse, lymph node tuberculosis, boils, and sore throat.

The Big Bammu is mixed with an extraction solvent in a weight ratio of 1:5 to 25, preferably 1:8 to 15, extracted at 50 to 80°C, and then concentrated under reduced pressure at 50 to 60°C to prepare an extract. When the weight ratio of the large snake radish and the extraction solvent is out of the above range, the active ingredient of the large snake radish may be extracted in a small amount in the extract.

When the extraction temperature is less than the lower limit, a small amount of active ingredients of the large snake radish may be extracted, and when the extraction temperature is greater than the upper limit, toxic substances may occur.

The extraction solvent for extracting each extract is water, a lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof. The lower alcohol may include 20 to 80% of methanol, ethanol, butanol or propanol.

The extraction solvent is not particularly limited, but the extract extracted with 20 to 80% ethanol aqueous solution is preferably used to improve, prevent or treat depressive symptoms, stress or cognitive dysfunction.

It was confirmed that the sucrose intake was increased to 65 to 85%, preferably 68 to 75% when ingesting the extract of the present invention, and thus, it was found to be advantageous in the improvement, prevention or treatment of stress or depression symptoms.

In addition, it was confirmed that when ingesting the extract of the present invention, the immobility time during forced swimming is as short as 80 to 120 seconds, and thus, it has been confirmed that it acts preferably in the improvement, prevention or treatment of depressive symptoms.

The term'extract' used in referring to the big snakemu in the present specification includes not only the crude extract obtained by treating the extraction solvent, but also the processed product of the big snakemu extract. For example, the big snake radish extract can be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.

In addition, the extract of the present invention has a meaning in a broad sense to include a processed product of a large snake, for example, a powder of a large snake, formulated to administer a large snake to an animal. Although the experiment was carried out in the present invention with a big snake mums, it would be predictable to those skilled in the art that the desired effect can be achieved even in the same form as the big snake mums.

On the other hand, in the present specification, the term "contained as an active ingredient" means containing an amount sufficient to achieve the efficacy or activity of the extract of the big snake. As an example, the extract is used in a concentration of 10 to 1500 ㎍ / ㎖, preferably 100 to 1000 ㎍ / ㎖. Since the big snake radish extract is a natural product and does not have side effects on the human body even if it is administered in an excessive amount, the upper limit of the quantity of the big snake radish extract included in the composition of the present invention can be selected and carried out by a person skilled in the art within an appropriate range.

The pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant includes excipients, disintegrants, sweeteners, binders, coating agents, expanding agents, lubricants, It is possible to use a lubricant or flavoring agent.

For administration, the pharmaceutical composition may contain one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients, and may be preferably formulated into a pharmaceutical composition.

The formulation form of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders are, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, lacquercanth or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

As acceptable pharmaceutical carriers for compositions formulated as liquid solutions, sterilization and biocompatible, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.

Furthermore, it can be preferably formulated according to each disease or ingredient using a method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration. .

A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, mode of administration, age, weight, sex, pathological condition, food, administration time, route of administration, excretion rate and response sensitivity of the patient, Usually, the skilled practitioner can readily determine and prescribe the dosage effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g/kg.

The pharmaceutical composition of the present invention may be prepared in a unit dosage form by formulation using a pharmaceutically acceptable carrier and/or excipient, or may be prepared by placing it in a multi-dose container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or a stabilizer.

In addition, the present invention provides a food composition for improving, preventing or treating depressive symptoms, stress or cognitive dysfunction, containing the extract of a large snake radish as an active ingredient.

The food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gum, ice cream, vitamin complexes, health supplements. Etc.

The food composition of the present invention may include not only the extract of a large snake radish as an active ingredient, but also ingredients that are commonly added during food production, and include, for example, proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents. . Examples of the aforementioned carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is made of drinks and beverages, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts, etc. may be further included in addition to the big snake radish extract of the present invention. .

The present invention provides a health functional food comprising a food composition for improving, preventing or treating depressive symptoms, stress or cognitive dysfunction comprising the extract of the big snake as an active ingredient. Health functional foods are foods prepared by adding, or encapsulating, powdering, or suspending large snake radish extract to food ingredients such as beverages, teas, spices, gums, confectionery, etc., which bring specific health effects when ingested. However, unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time by using food as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis. In such health functional foods, the amount of Bammu extract added can not be uniformly regulated depending on the type of health functional food to be targeted, but it can be added within the range that does not damage the original taste of the food. It is in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight. In addition, in the case of health functional foods in the form of pills, granules, tablets or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.

In addition, the present invention provides a use of a large snake radish extract for the manufacture of a medicine or food for improving, preventing or treating depressive symptoms, stress or cognitive dysfunction. As described above, the extract can be used for improving, preventing or treating depressive symptoms, stress or cognitive dysfunction.

In addition, the present invention provides a method for improving, preventing or treating depressive symptoms, stress or cognitive dysfunction, comprising administering an effective amount of the extract to a mammal.

The term "mammal" as used herein refers to a mammal that is the subject of treatment, observation or experimentation, and preferably refers to a human.

The term "effective amount" as used herein refers to the amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, which is considered by a researcher, veterinarian, doctor or other clinician, Includes an amount that induces relief of symptoms of the disease or disorder. The effective amount and the number of administrations for the active ingredient of the present invention may vary depending on the desired effect. Therefore, the optimal dosage to be administered can be easily determined by those skilled in the art, and the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, and general health of the patient. It can be adjusted according to various factors including condition, sex and diet, time of administration, route of administration and secretion rate of the composition, duration of treatment, and drugs used simultaneously. In the prevention, treatment or improvement method of the present invention, in the case of an adult, when a mixed extract of Mokdanpi, Baekbokryeong, Taeksa and Dansam is administered once to several times a day, it is administered at a dose of 0.001 g/kg to 10 g/kg. It is desirable.

In the treatment method of the present invention, the composition comprising the extract of chinensis radish as an active ingredient is a conventional method through oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes. Can be administered.

In addition, it is possible to provide a feed additive composition comprising the extract of the present invention as an active ingredient, and as animals suitable for ingesting the feed additive composition, poultry of livestock (laying chickens, ducks, turkeys, geese, etc.) and ruminants It includes (cows, horses, goats, sheep, etc.), pigs (pigs), rodents (rabbits, mice), puppies, cats, and fish, and can be used extensively and usefully.

Substances included in the feed additive composition of the present invention in addition to the extract of large snake radish are not particularly limited as long as they are used in conventional feed compositions for livestock.

Hereinafter, a preferred embodiment is presented to aid the understanding of the present invention, but the following examples are only illustrative of the present invention, and it is obvious to those skilled in the art that various changes and modifications are possible within the scope and spirit of the present invention, It is natural that such modifications and modifications fall within the appended claims.

Example 1. Use of 70% ethanol aqueous solution

A large snake radish and a 70% aqueous ethanol solution were mixed at a weight ratio of 1: 10 and extracted at 60° C. for 3 hours to obtain a large snake radish extract.

Example 2. Use of water

It was carried out in the same manner as in Example 1, except that water was used instead of an 80% aqueous ethanol solution as an extraction solvent to obtain a big snake radish extract.

<Test Example>

Prepared in the examples After filtering the extract, the filtrate was concentrated under reduced pressure at 60° C. or lower and used.

Cell experiment

To measure the neuronal protective effect, SH-SY5Y, a human neuroblastoma cell line, was distributed and used from ATCC (Manassas, VA, USA), and 10% fetal bovine serum (Gibco, Carlsbad, CA, USA) and 1% penicillin streptomycin were used. It was cultured at 37°C and 5% CO2 using the added Dulbecco's modified Eagle medium medium, and subcultured at intervals of 2 to 3 days.

Test Example 1. Measurement of protective effect on cranial nerve cells

Cultured SH-SY5Y cells were dispensed in a 96-well plate at a concentration of 2.5X10 ⁴ cells/well and incubated for 1 day, and then 200 μM dexamethasone was added to induce brain neurocytotoxicity. 10, 50, 100 μM) and incubated for an additional 48 hours. Cell viability was confirmed through the MTT assay method. That is, pMTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide, Sigma Co., USA) solution (0.3 mg/mL. final conc.) of 20 μL per well. After applying, incubation for 4 hours and removal of the culture medium, 150 μL of dimethylsulfoxide (DMSO) was added each to dissolve MTT formazan while leaving for 5 minutes. After 5 minutes, absorbance (450 nm, 25 ℃) was measured with an ELISA reader, and control It is expressed as a percentage of the survival rate.

-9 groups of cell treatment groups-

Normal group: culture after administration of physiological saline

Control 1: culture after addition of 200 μM dexamethasone

Control 2: 200 μM dexamethasone added + imipramine, an existing antidepressant, and St. Culture after administration of John's wort

Example 1 (10): 200 μM dexamethasone added + 10 μM of the extract of Example 1 after treatment

Example 1 (50): 200 μM dexamethasone added + 50 μM of the extract of Example 1 after treatment

Example 1 (100): 200 μM dexamethasone added + 100 μM of the extract of Example 1 after treatment

Example 2 (10): 200 μM dexamethasone addition + 10 μM of the extract of Example 2 after treatment

Example 2 (50): 200 μM dexamethasone added + 50 μM of the extract of Example 2 after treatment

Example 2 (100): 200 μM dexamethasone added + 100 μM of the extract of Example 2 after treatment

division Normal Control 1 Control 2 Example 1 (10) Example 1 (50) Example 1 (100) Example 2 (10) Example 2 (50) Example 2 (100) Cell viability
(%) 100 58.4 80.5 70.7 92.6 121.5 62.4 72.4 82.9

As shown in Table 1 above, the cell line to which dexamethasone (DEX) was added showed a cell viability of 58.4% depending on cytotoxicity, but in Example 1 to which the Ethanol extract was added, cell viability of 70 to 121.5% was shown. Confirmed. It was confirmed that the cell lines treated in Example 1 at concentrations of 50 and 100 μM showed superior cell viability even compared to the control group 2 using the existing antidepressant.

On the other hand, it was confirmed that the cell viability of Example 2 to which the water extract was added showed a cell viability of 62 to 83%, so that the cell viability was lower or similar to that of the control group 2.

Animal experiment

250-300 g of ICR mice (5 weeks old, Coretech, Korea, male) were used in the experiment. It was bred in an acrylic cage (45 X 60 X 25 cm), provided with sufficient feed and water, and controlled the day and night for 12 hours with appropriate artificial illumination (from 8:00 am to daytime). And it maintained a constant temperature (20 ~ 24 ℃) and humidity (45 ~ 65%). They looked for a week to adapt to the changed environment, maintained the sleep cycle, and confirmed abnormal behavior.

The animal protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the Korea Food Research Institute.

Experimental animals were selected only healthy animals with constant weight change, the extracts of Examples 1 and 2 to the normal group administered with physiological saline, the control group administered with dexamethasone, and the group administered with dexamethasone. The samples were divided into administration groups, and 5 animals were used for each experimental group.

At this time, dexamethasone was administered by injection at a constant time of 40 mg/kg once a day for 7 days, and the extracts of Examples 1 and 2 were dissolved in saline at the following concentrations (200, 300 mg/kg), and 100 ul oral After administration, a behavioral test was conducted 60 minutes later.

-7 groups of mice-

Normal group: 5 mice administered physiological saline for 7 days_40 mg/kg/day

Control 1: 5 mice administered dexamethasone 7 days_40 mg/kg/day

Control group 2: Dexamethasone 7-day administration_40 mg/kg/day + 30 mg/kg of imipramine, an existing antidepressant, and St. John's wort administration_300 mg/kg (oral administration)

Example 1 (200): 7 days of dexamethasone administration_40 mg/kg/day + 200 mg/kg of extract of Example 1

Example 1 (300): 7 days of dexamethasone administration_40 mg/kg/day + 300 mg/kg of extract of Example 1

Example 2 (200): 7-day administration of dexamethasone_40 mg/kg/day + 200 mg/kg of extract of Example 2

Example 2 (300): 7-day administration of dexamethasone_40 mg/kg/day + 300 mg/kg of extract of Example 2

Test Example 2. Measurement of sucrose preference test

Sucrose intake is a representative indicator of anhedonia response, one of the symptoms of stress or depression. Accordingly, the amount of sucrose intake was measured and shown in Table 2 below.

division Normal Control 1 Control 2 Example 1 (200) Example 1 (300) Example 2 (200) Example 2 (300) Sucrose intake
(%) 82.1 48.5 67.1 62.5 67.8 55.1 61.8

As shown in Table 2 above, it was confirmed that the sucrose intake was higher than that of the control group 1 and 2 in the extracts of the big snake mums prepared according to Examples 1 and 2 of the present invention.

In addition, 300 mg/kg of the ethanol extract of Bammu of Example 1 administered in the same amount as that of the control group 2 showed a similar sucrose intake to that of the control group 2, whereas the water extract of Bammu of practical example 2 had a lower sucrose intake than that of the control group 2. Confirmed.

That is, it was confirmed that the extract of the big snake radish of Example 1 increases the sucrose intake significantly decreased due to stress or depression symptoms to the level of a normal state.

Test Example 3. Immobility time measurement

Through the forced swimming experiment, an antidepressant experiment on evasion ability in emergency situations was performed from a behavioral pharmacological perspective.

To measure the forced swim test (FST), a transparent beaker with a height of 30 cm or more was filled with water (temperature 23-25° C.) by 15 cm, and mice were obtained and forced to swim for 6 minutes. It was acquired and recorded as a digital video file for 6 minutes, and the immobility and swimming time were analyzed using a behavior analysis program (SMART v3.0, Panlab SL, Barcelona, Spain). For each result, immobility time and swimming time were analyzed for the remaining 4 minutes excluding the first 2 minutes.

division Normal Control 1 Control 2 Example 1 (200) Example 1 (300) Example 2 (200) Example 2 (300) Floating time
(sec) 90.5 169.5 98.5 91.4 89.7 115.5 105.1

As shown in Table 3 above, compared to the group to which dexamethasone was administered (control 1), the immobility time was significantly reduced and the moving time was compared to the group administered with dexamethasone (control 1). It was confirmed that the (swimming time) increased.

In addition, 300 mg/kg of the ethanol extract of Example 1, which was administered in the same amount as that of the control group 2, reduced the immobility time compared to the control group 2, whereas the water extract of the water extract of practical example 2 was Compared to that, it was confirmed that the immobility time increased.

This means that the extracts of Examples 1 and 2 are effective against antidepressant, and furthermore, the extract of Example 1 has more antidepressant efficacy than the extract of Example 2.

In addition, due to the forced swimming experiment, it was confirmed that the ethanol extract of Example 1 decreases the still time and increases the moving time, so that the exercise time increases. Accordingly, since the ethanol extract of Example 1 is excellent in improving exercise capacity, it can be used as a food composition for improving exercise capacity.

Test Example 4. Passive avoidance test

A passive avoidance device (GEMINI avoidance system, SD instrument, CA, USA) was used to measure the cognitive function improvement efficacy of the extract of the big snake radish. There are chambers of 24 cm X 20 cm X 20 cm on both sides with the guillotine door in the middle, and the floor of each chamber has a grid so that the current flows in the dark room. When the experimental animal is placed in the right chamber, the chamber lights up after 10 seconds of acclimation time, and the guillotine door opens at the same time. At this time, the mouse moves to a dark place due to its instinct to move to the dark part, which is a method of measuring and evaluating the step through latency of the mouse. The moment the mouse enters the dark room, the guillotine door closes, and an electric shock was applied to the mouse entering the dark room by flowing a current of 0.5 ㎃ through the grid on the floor for 2 seconds. When the mouse was taken out, moved to the cage, and the guillotine door was opened again after 24 hours elapsed, the electric shock of the previous day was memorized and the time of not entering the black part of the box was measured to evaluate cognitive function.

The following [Table 4] shows the results of improving the cognitive function of mice that are reduced according to confinement stress for 6 hours and 3 weeks once a day.

division Normal Control 1 Control 2 Example 1 (200) Example 1 (300) Example 2 (200) Example 2 (300) Passive avoidance ability
(sec) 199.4 31.2 89.7 107.1 112.5 71.5 80.6

As shown in Table 4 above, the control group 1, who was given confinement stress for a long time, showed a behavior according to cognitive impairment significantly compared to the normal group not receiving confinement stress.

It was confirmed that the ethanol extract of Ethanol extract prepared according to Example 1 of the present invention significantly improved cognitive decline due to stress compared to the group to which dexamethasone was administered (control group 1) and control group 2. Compared to the group to which dexamethasone was administered (control 1), the water extract prepared according to Example 2 significantly improved the cognitive decline due to stress, but compared to the control group 2, the cognitive decline due to stress was applied. It was confirmed that it could not be improved.

In other words, it was confirmed that the ethanol extract of Example 1 significantly improved the cognitive decline due to stress, compared with the water extract of Example 2.

This means that the extracts of Examples 1 and 2 are effective in improving, preventing or treating cognitive function, and in particular, the extract of Example 1 is effective in improving, preventing or treating cognitive function compared to the extract of Example 2. do.

Hereinafter, examples of the formulation of the composition containing the powder of the present invention will be described, but the present invention is not intended to limit it, but is intended to be described in detail.

Formulation Example 1. Preparation of powder

500 mg of extract powder obtained in Example 1

100 mg lactose

10 mg of talc

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2. Preparation of tablet

300 mg of extract powder obtained in Example 1

100 mg corn starch

100 mg lactose

2 mg of magnesium stearate

After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet preparation method.

Formulation Example 3. Preparation of Capsule

200 mg of extract powder obtained in Example 1

3 mg of crystalline cellulose

14.8 mg lactose

Magnesium stearate 0.2 mg

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare a capsule.

Formulation Example 4. Preparation of injection

600 mg of extract powder obtained in Example 1

Mannitol 180 mg

2974 mg of sterile distilled water for injection

Na ₂ HPO _4, 12H ₂ O 26 mg

It is prepared with the above ingredients per ampoule according to a conventional injection preparation method.

Formulation Example 5. Preparation of liquid formulation

4 g of extract powder obtained in Example 1

10 g of isomerized sugar

5 g of mannitol

Purified water appropriate amount

According to the usual preparation method of liquid preparation, add and dissolve each component in purified water, add an appropriate amount of lemon scent, mix the above ingredients, add purified water and add purified water to adjust the total to 100 g, then fill in a brown bottle for sterilization. To prepare a solution.

Formulation Example 6. Preparation of granules

1,000 mg of extract powder obtained in Example 1

Vitamin mixture right amount

Vitamin A acetate 70 ㎍

1.0 mg of vitamin E

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

0.5 mg of vitamin B6

Vitamin B12 0.2 ㎍

Vitamin C 10 mg

Biotin 10 ㎍

1.7 mg of nicotinic acid amide

Folic acid 50 ㎍

0.5 mg of calcium pantothenate

Suitable amount of inorganic mixture

1.75 mg ferrous sulfate

Zinc oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dicalcium phosphate 55 mg

90 mg of potassium citrate

100 mg of calcium carbonate

Magnesium chloride 24.8 mg

The composition ratio of the vitamin and mineral mixture is relatively suitable for granules, but it is possible to arbitrarily modify the mixing ratio. After mixing the above ingredients according to a conventional granule preparation method, granules And can be used to prepare a health functional food composition according to a conventional method.

Formulation Example 7. Preparation of functional beverage

1,000 mg of extract powder obtained in Example 1

1,000 mg citric acid

100 g oligosaccharides

2 g of plum concentrate

1 g taurine

Total 900 mL with purified water

After mixing the above ingredients according to a normal health drink manufacturing method, stirring and heating the resulting solution at 85°C for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed and sterilized, and stored in a refrigerator It is used to prepare the functional beverage composition of the invention.

The composition ratio is composed of ingredients suitable for a relatively preferred beverage in a preferred embodiment, but the mixing ratio may be arbitrarily modified according to regional and ethnic preferences, such as the demand class, the country of demand, and the purpose of use.

Claims (13)

A pharmaceutical composition for the prevention or treatment of depressive symptoms or stress, characterized in that it contains the extract of Geum aleppicum as an active ingredient. The pharmaceutical composition for preventing or treating depressive symptoms or stress according to claim 1, wherein the extract is extracted with water, a lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof. The pharmaceutical composition for preventing or treating depressive symptoms or stress according to claim 2, wherein the lower alcohol having 1 to 4 carbon atoms is 20 to 80% methanol, ethanol, butanol or propanol. The pharmaceutical composition for preventing or treating depression symptoms or stress according to claim 1, wherein the extract is extracted with 20 to 80% ethanol aqueous solution. The pharmaceutical composition for preventing or treating depressive symptoms or stress according to claim 1, wherein the extraction temperature is 50 to 80°C. The pharmaceutical composition for preventing or treating depression symptoms or stress according to claim 1, wherein the intake amount of sucrose when ingesting the pharmaceutical composition is 65 to 85% (V/V). The pharmaceutical composition for preventing or treating depressive symptoms or stress according to claim 1, wherein the immobility time is 80 to 120 seconds during forced swimming after ingestion of the pharmaceutical composition. A food composition for improving or preventing depressive symptoms or stress, characterized in that it contains the extract of Geum aleppicum as an active ingredient. The food composition for improving or preventing depression symptoms or stress according to claim 8, wherein the extract is extracted with an aqueous ethanol solution of 20 to 80%. The food composition for improving or preventing depressive symptoms or stress according to claim 8, wherein the sucrose intake amount when ingesting the food composition is 65 to 85% (V/V). The food composition for improving or preventing depressive symptoms or stress according to claim 8, wherein the immobility time is 80 to 120 seconds during forced swimming after ingesting the food composition. delete delete